Nasal spray could tame brain inflammation in progressive MS
NCT ID NCT06292923
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, or a placebo for 12 weeks, and researchers will check safety and measure brain inflammation using PET scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Foralumab (a human antibody given as a nasal spray)
- What this could lead to
- If it works, this could point toward a new way to slow disability progression in secondary progressive MS without injections or infusions.
- What could go wrong
- This is an early phase 2a trial with only 54 people, so results may not confirm benefit. The main goal is safety and brain imaging changes, not yet proven to help symptoms or disability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Cornell Weill Medical Center
New York, New York, 10021, United States
-
Johns Hopkins
Baltimore, Maryland, 21287, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
University of Buffalo
Buffalo, New York, 14202, United States
-
University of Massachusetts
Worcester, Massachusetts, 01655, United States
-
Yale
North Haven, Connecticut, 06473, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Can an Iron-Based dye reveal hidden inflammation in progressive MS?
- Could a common supplement fight fatigue in progressive MS?
- Nurse-Led video calls aim to empower MS patients
- Cheaper MS drug could match pricey standard in major trial
- Experimental cell therapy takes on multiple sclerosis